Exploring how tumor microenvironment changes affect treatment for esophageal cancer
Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Renmin Hospital of Wuhan University · NCT05894369
This study is testing how changes in inflammation and the tumor environment affect the success of treatment for patients with esophageal cancer who are receiving chemotherapy and immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Renmin Hospital of Wuhan University (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05894369 on ClinicalTrials.gov |
What this trial studies
This study evaluates the role of inflammatory factors in the blood and their predictive value on the prognosis of patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy combined with immunotherapy. It aims to collect baseline patient information and laboratory data before and during treatment to understand how inflammation and the tumor microenvironment influence treatment efficacy. The study will involve patients admitted to Hubei Provincial People's Hospital from May 2023 to December 2024, with a target enrollment of 60 participants.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 with a confirmed diagnosis of esophageal squamous cell carcinoma at clinical stages II-IVA who are eligible for neoadjuvant therapy.
Not a fit: Patients with a life expectancy of less than 6 months, those with distant metastasis at diagnosis, or individuals with other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with esophageal cancer, enhancing their overall survival rates.
How similar studies have performed: While this approach is exploring new mechanisms, similar studies have shown promise in understanding the tumor microenvironment's impact on treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria： The patient's age between 18 to 80 years old; Esophageal squamous cell carcinoma with definite pathological diagnosis and II-IVA clinical stage Preoperative neoadjuvant chemotherapy combined with immunotherapy The score of eastern cooperative oncology group is 0 \~ 1 Exclusion criteria The estimated survival time is less than 6 months; The first diagnosis had distant metastasis Suffering from malignant tumor or accompanying malignant disease in the past 5 years Pregnant or pregnant women. Vulnerable groups (those without informed ability, minors, vagrants, students and subordinates of researchers, employees of bidders)
Where this trial is running
Wuhan, Hubei
- Renmin hosptial of Wuhan University — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Study coordinator: Yong Shun Chen
- Email: yongshun2007@163.com
- Phone: 86+153 2712 2084
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Esophageal Cancer, neoadjuvant therapy, immunotherapy, overall survival, efficacy, safety